Download PDF
Thromb Haemost 1998; 79(01): 228-233
DOI: 10.1055/s-0037-1614244
Review Article
Schattauer GmbH

Ecarin Clotting Time: a Predictive Coagulation Assay for the Antithrombotic Activity of Argatroban in the Rat

Christopher N. Berry
1   From the Thrombosis and Haematology Dept., Direction Cardio-vasculaire, Synthélabo Recherche, Bagneux, France
,
Catherine Lunven
1   From the Thrombosis and Haematology Dept., Direction Cardio-vasculaire, Synthélabo Recherche, Bagneux, France
,
Christine Girardot
1   From the Thrombosis and Haematology Dept., Direction Cardio-vasculaire, Synthélabo Recherche, Bagneux, France
,
Irène Lechaire
1   From the Thrombosis and Haematology Dept., Direction Cardio-vasculaire, Synthélabo Recherche, Bagneux, France
,
Denise Girard
1   From the Thrombosis and Haematology Dept., Direction Cardio-vasculaire, Synthélabo Recherche, Bagneux, France
,
Marie-Christine Charles
1   From the Thrombosis and Haematology Dept., Direction Cardio-vasculaire, Synthélabo Recherche, Bagneux, France
,
Patrice Ferrari
1   From the Thrombosis and Haematology Dept., Direction Cardio-vasculaire, Synthélabo Recherche, Bagneux, France
,
Donogh P. O’Brien
1   From the Thrombosis and Haematology Dept., Direction Cardio-vasculaire, Synthélabo Recherche, Bagneux, France
› Author Affiliations
Further Information

Publication History

Received 05 May 1997

Accepted after resubmission 03 September 1997

Publication Date:
08 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

We studied the use of the Ecarin Clotting Time (ECT) as a predictive assay of the antithrombotic effects of argatroban in a new tissue factor-dependent model of venous thrombosis and a model of arterial thrombosis in the rat. Heparin was used as a reference anticoagulant.

Infusions of argatroban dose-dependently increased the ECT across the range of doses required for antithrombotic activity in models of venous and arterial thrombosis (1.25-40 μg/kg/min). The TT was only useful as a marker in the case of venous thrombosis, since, in the arterial thrombosis model, the clotting times were >200 s in the majority of animals receiving antithrombotic doses. The aPTT is not sufficiently sensitive to be predictive of an antithrombotic effect in the venous model, and shows only modest increases in the arterial thrombosis model. Heparin did not significantly increase the ECT at antithrombotic doses in the venous thrombosis model, and only increased the ECT by 53% at 40 μg/kg/min in the arterial model, despite a marked antithrombotic effect. Both the TT and aPTT were dose-dependently increased by heparin at doses active in the venous model, whereas both parameters were >200 s at doses active in the arterial thrombosis model.

Thus, the ECT provides a predictive marker for the antithrombotic activity of argatroban in both venous and arterial thrombosis, at least in the rat.

 

  • References

  • 1 Berry CN, Girard D, Lochot S, Lecoffre C. Antithrombotic actions of argatroban in rat models of venous, ‘mixed’ and arterial thrombosis, and its effects on the tail transection bleeding time.. Br J Pharmacol 1994; 113: 1209-14.
    CrossrefPubMedGoogle Scholar
  • 2 Carteaux J-P, Gast A, Tschopp T, Roux S. Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro46-6240 in experimental arterial thrombosis.. Circulation 1995; 91: 1568-74.
    CrossrefPubMedGoogle Scholar
  • 3 Peters RF, Lees CM, Mitchell KA, Tweed MF, Talbot MD, Wallis RB. The characterisation of thrombus development in an improved model of arteriovenous shunt thrombosis in the rat and the effects of recombinant desulphatohirudin (CGP 39393), heparin, and iloprost.. Thromb Haemost 1991; 65: 268-74.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Bucha E, Nowak G. The Ecarin Coagulation Time (ECT) the first specific method suited for quick determination of direct thrombin inhibitors in whole blood, plasma and body fluids.. Int Angiology 1995; 14 (Suppl. 01) 174.
    PubMedGoogle Scholar
  • 5 Kornalik F, Blombäck B. Prothrombin activation induced by ecarin – a pro thrombin converting enzyme from Echis carinatus venom.. Thromb Res 1975; 6: 53-63.
    CrossrefPubMedGoogle Scholar
  • 6 Callas DD, Fareed J. Comparative anticoagulant effects of various thrombin inhibitors, as determined in the ecarin clotting time method.. Thromb Res 1996; 83: 463-8.
    CrossrefPubMedGoogle Scholar
  • 7 Kikumoto R, Tamao Y, Tezuka T, Tonomura S, Hara H, Ninomiya K, Hijikata A, Okamoto S. Selective inhibition of thrombin by (2R4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-L-Arginyl)]-2-piperidinecarboxylic acid.. Biochemistry 1984; 23: 85-90.
    CrossrefPubMedGoogle Scholar
  • 8 Okamoto S, Hijikata A, Kikumoto R, Tonomara S, Hara H, Ninomiya K, Maruyama A, Sugano M, Tamao Y. Potent Inhibition of Thrombin by the Newly Synthesized Arginine Derivative No. 805. The Importance of Stereo-Structure of its Hydrophobic Carboxamide Portion.. Biochem Biophys Res Commun 1981; 101: 440-6.
    CrossrefPubMedGoogle Scholar
  • 9 Tamao Y, Yamamoto T, Kikumoto R, Hara H, Itoh J, Hirata T, Mineo K, Okamoto S. Effect of a selective thrombin inhibitor MCI-9038 on fibrinolysis in vitro and in vivo.. Thromb Haemost 1986; 56: 28-34.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Imura Y, Stassen J-M, Collen D. Comparative Antithrombotic Effects of Heparin, Recombinant Hirudin and Argatroban in a Hamster Femoral Vein Platelet-Rich Mural Thrombosis Model.. J Pharm Exp Ther 1992; 261: 895-8.
    PubMedGoogle Scholar
  • 11 Jang IK, Gold HK, Ziskind AA, Leinbach RC, Fallon JT, Collen D. Prevention of Platelet-Rich Arterial Thrombosis by Selective Thrombin Inhibition.. Circulation 1990; 81: 219-25.
    CrossrefPubMedGoogle Scholar
  • 12 Fujioka K. The Effect of MD-805 on Experimental Acute Arterial Thrombosis in Relation to Vasoactive Prostanoids (TXA2 and PGI2).. J Jap Coll Angiol 1989; 29: 57-64.
    PubMedGoogle Scholar
  • 13 Eidt JF, Allison P, Noble S, Ashton J, Golino P, Mcnatt J, Buja LM, Willerson JT. Thrombin is an Important Mediator of Platelet Aggregation in Stenosed Canine Coronary Arteries with Endothelial Injury.. J Clin Invest 1989; 84: 18-27.
    CrossrefPubMedGoogle Scholar
  • 14 Duval N, Lunven C, O’Brien DP, Grosset A, O’Connor SE, Berry CN. Antithrombotic actions of the thrombin inhibitor, argatroban, in a canine model of coronary cyclic flow: comparison with heparin.. Br J Pharmacol 1996; 118: 727-33.
    CrossrefPubMedGoogle Scholar
  • 15 Schumacher WA, Heran CL, Steinbacher TE. Low molecular weight heparin (Fragmin) and thrombin active site inhibitor (Argatroban) compared in experimental arterial thrombosis and bleeding time.. J Cardiovascular Pharmacol 1996; 28: 19-25.
    CrossrefPubMedGoogle Scholar
  • 16 Hladovec J. Experimental thrombosis in rats with continuous registration.. Thromb Haemost 1971; 26: 407-10.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Berry CN, Lunven C, O’Brien DP, Girardot C, Girard D, Charles MC, Ferrari P. Ecarin clotting time: a predictive marker for the antithrombotic effects of argatroban in rat venous and arterial thrombosis.. Thromb Haemost. 1998 77. (Suppl) 92.
    PubMedGoogle Scholar
  • 18 Béguin S, Lindhout T, Hemker C. The mode of action of heparin in plasma.. Thromb Haemost 1988; 60: 457-62.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 GUSTO IIa investigators.. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes.. Circulation 1994; 90: 1631-7.
    CrossrefPubMedGoogle Scholar
  • 20 Verstraete M, Nurmohamed M, Kienast J, Siebeck M, Silling-Engel-hardt G, Büller H, Hoet B, Bichler J, Close P. Biological effects of recombinant hirudin (CGP 39393) in human volunteers.. JACC 1993; 22: 1080-8.
    CrossrefPubMedGoogle Scholar
  • 21 Marbert GA, Verstraete M, Kienast J, Graf P, Hoet B, Tsakiris DA, Silling-Engel-hardt G, Close P. Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers.. J Cardiovasc Pharm 1993; 22: 364-72.
    CrossrefPubMedGoogle Scholar
  • 22 Nurmohamed MT, Berckmans RJ, Morrien-Salomons WM, Berends F, Hammes WD, Rijnierse JJMM, Sturk A. Monitoring anticoagulant therapy by activated partial thromboplastin time: Hirudin assessment.. Thromb Haemost 1994; 72: 685-92.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Schwarz RP, Becker JCP, Brooks RL, Joffrion JL, Knappenberger GD, Kogan TP, Kogan PW, McKinney AA. The preclinical and clinical pharmacology of Novastan (argatroban): a small-molecule, direct thrombin inhibitor.. J Clin Appl Thromb Hemost. 1998 (in press).
    PubMedGoogle Scholar
  • 24 Pötzsch B, Madlener K, Seelig C, Riess CF, Greinacher A, Müller-Berghaus G. Monitoring of r-hirudin anticoagulation during cardiopulmo-nary bypass – Assessment of the whole blood ecarin clotting time.. Thromb Haemost 1998; 77: 920-5.
    PubMedGoogle Scholar
  • 25 Mize PD, Ruebsaman K. Dry-chemistry ecarin clotting time for ex vivo monitoring of thrombin inhibitors.. Thromb Haemost. 1998 77. (Suppl.) 436.
    PubMedGoogle Scholar
  • 26 Lewis BE, Iqbal O, Hoppensteadt D, Ahsan A, Ahmad S, Messmore HL, Schwarz RP, Walenga JM. Clinical pharmacokinetic and pharmacodynamic studies on argatroban to optimize the anticoagulant dosage in interventional cardiovascular procedures.. Thromb Haemost 1998; 77 (Suppl.) 492.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Morita T, Iwanaga S, Suzuki T. The mechanism of activation of bovine prothrombin by an activator isolated from Echis carinatus venom and characterization of the new active intermediates.. J Biochem 1976; 79: 1089-108.
    CrossrefPubMedGoogle Scholar
  • 28 Verstraete M. Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins.. Drugs 1990; 40: 498-530.
    CrossrefPubMedGoogle Scholar
  • 29 Stocker K, Fischer H, Brogli M. Chromogenic assay for the prothrombin activator ecarin from the venom of the saw-scaled viper (Echis carinatus).. Toxicon 1986; 24: 81-9.
    CrossrefPubMedGoogle Scholar